Core Viewpoint - The company has approved a comprehensive credit financing limit of up to RMB 650 million and a guarantee limit of up to RMB 600 million for itself and its subsidiaries, aimed at supporting business operations and development [2][5]. Group 1: Guarantee Adjustment Situation - The company has adjusted the unused guarantee limits of its subsidiaries, transferring a total of RMB 16 million to its wholly-owned subsidiary Hefei Yifan Pharmaceutical Co., Ltd. (合肥亿帆) [3]. - After the adjustment, the guarantee limits for Sichuan Defeng Pharmaceutical Co., Ltd., Anqing Xinfuhua Chemical Co., Ltd., and Xinfuhua Technology Co., Ltd. have been reduced to zero, while the limit for Hefei Yifan has increased from RMB 88 million to RMB 104 million [3]. Group 2: Guarantee Overview - The company signed an irrevocable maximum guarantee agreement with China Merchants Bank Hefei Branch, agreeing to provide a joint liability guarantee for Hefei Yifan's debts, with a maximum guarantee amount of RMB 10 million [4]. - The guarantee is valid for the duration of the loans or financing agreements under the credit agreement, extending three years beyond the maturity of each loan [9]. Group 3: Financial and Operational Context - Hefei Yifan, established on September 9, 2022, is a wholly-owned subsidiary of the company, with a registered capital of RMB 100 million and involved in various pharmaceutical and medical-related activities [6][7]. - The company has confirmed that Hefei Yifan is not a dishonest executor and has the capability to repay its debts [10]. Group 4: Cumulative Guarantee Situation - As of the report date, the total external guarantee balance of the company and its subsidiaries is RMB 5.132 billion, accounting for 60.22% of the company's audited net assets for 2024 [11].
亿帆医药股份有限公司 关于在下属子公司之间调剂担保额度及为全资子公司提供担保的进展公告